Contemporary strategies for the prevention of stress-related mucosal bleeding

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose. The purpose of this review is to describe the clinical presentation and pathophysiology of stress-related mucosal bleeding and review the strategies to prevent bleeding. Summary. The mortality rate associated with clinically significant stress-related mucosal bleeding is high. Respiratory failure requiring mechanical ventilation for more than 48 hours and coagulopathy are two strong, independent risk factors for bleeding. Splanchnic hypoperfusion is the underlying etiology of stress-related mucosal injury and bleeding. Mucosal damage typically manifests as multiple superficial lesions without perforation, and bleeding often originates in superficial capillaries after the patient is admitted to the intensive care unit. Providing adequate visceral perfusion is vital to preventing bleeding. Gastrointestinal function should be taken into consideration before using enteral nutrition, and enteral nutrition should not be the sole stress ulcer prophylactic therapy. Acid-suppression therapy should be used to raise the intragastric pH above 3.5 because it reduces the incidence of stress-related mucosal bleeding. Proton pump inhibitors are at least as effective, and may be more effective than histamine H 2-receptor antagonists in achieving this pH goal and preventing bleeding. Conclusion. The key to reducing mortality from stress-related bleeding in critically ill patients is to prevent mucosal damage. Providing adequate visceral perfusion and acid-suppression therapy can reduce the risk of stress-related mucosal damage and bleeding.

Original languageEnglish (US)
JournalAmerican Journal of Health-System Pharmacy
Volume62
Issue numberSUPPL. 2
StatePublished - May 15 2005
Externally publishedYes

Fingerprint

Hemorrhage
Enteral Nutrition
Perfusion
Acids
Viscera
Mortality
Proton Pump Inhibitors
Artificial Respiration
Critical Illness
Respiratory Insufficiency
Histamine
Ulcer
Intensive Care Units
Therapeutics
Incidence
Wounds and Injuries

Keywords

  • Critical illness
  • Gastrointestinal drugs
  • Gastrointestinal hemorrhage
  • Mortality
  • Nutrition
  • Tolerance

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Contemporary strategies for the prevention of stress-related mucosal bleeding. / Martindale, Robert.

In: American Journal of Health-System Pharmacy, Vol. 62, No. SUPPL. 2, 15.05.2005.

Research output: Contribution to journalArticle

@article{e444d5eff5c44e6094998b8e6d79f540,
title = "Contemporary strategies for the prevention of stress-related mucosal bleeding",
abstract = "Purpose. The purpose of this review is to describe the clinical presentation and pathophysiology of stress-related mucosal bleeding and review the strategies to prevent bleeding. Summary. The mortality rate associated with clinically significant stress-related mucosal bleeding is high. Respiratory failure requiring mechanical ventilation for more than 48 hours and coagulopathy are two strong, independent risk factors for bleeding. Splanchnic hypoperfusion is the underlying etiology of stress-related mucosal injury and bleeding. Mucosal damage typically manifests as multiple superficial lesions without perforation, and bleeding often originates in superficial capillaries after the patient is admitted to the intensive care unit. Providing adequate visceral perfusion is vital to preventing bleeding. Gastrointestinal function should be taken into consideration before using enteral nutrition, and enteral nutrition should not be the sole stress ulcer prophylactic therapy. Acid-suppression therapy should be used to raise the intragastric pH above 3.5 because it reduces the incidence of stress-related mucosal bleeding. Proton pump inhibitors are at least as effective, and may be more effective than histamine H 2-receptor antagonists in achieving this pH goal and preventing bleeding. Conclusion. The key to reducing mortality from stress-related bleeding in critically ill patients is to prevent mucosal damage. Providing adequate visceral perfusion and acid-suppression therapy can reduce the risk of stress-related mucosal damage and bleeding.",
keywords = "Critical illness, Gastrointestinal drugs, Gastrointestinal hemorrhage, Mortality, Nutrition, Tolerance",
author = "Robert Martindale",
year = "2005",
month = "5",
day = "15",
language = "English (US)",
volume = "62",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Contemporary strategies for the prevention of stress-related mucosal bleeding

AU - Martindale, Robert

PY - 2005/5/15

Y1 - 2005/5/15

N2 - Purpose. The purpose of this review is to describe the clinical presentation and pathophysiology of stress-related mucosal bleeding and review the strategies to prevent bleeding. Summary. The mortality rate associated with clinically significant stress-related mucosal bleeding is high. Respiratory failure requiring mechanical ventilation for more than 48 hours and coagulopathy are two strong, independent risk factors for bleeding. Splanchnic hypoperfusion is the underlying etiology of stress-related mucosal injury and bleeding. Mucosal damage typically manifests as multiple superficial lesions without perforation, and bleeding often originates in superficial capillaries after the patient is admitted to the intensive care unit. Providing adequate visceral perfusion is vital to preventing bleeding. Gastrointestinal function should be taken into consideration before using enteral nutrition, and enteral nutrition should not be the sole stress ulcer prophylactic therapy. Acid-suppression therapy should be used to raise the intragastric pH above 3.5 because it reduces the incidence of stress-related mucosal bleeding. Proton pump inhibitors are at least as effective, and may be more effective than histamine H 2-receptor antagonists in achieving this pH goal and preventing bleeding. Conclusion. The key to reducing mortality from stress-related bleeding in critically ill patients is to prevent mucosal damage. Providing adequate visceral perfusion and acid-suppression therapy can reduce the risk of stress-related mucosal damage and bleeding.

AB - Purpose. The purpose of this review is to describe the clinical presentation and pathophysiology of stress-related mucosal bleeding and review the strategies to prevent bleeding. Summary. The mortality rate associated with clinically significant stress-related mucosal bleeding is high. Respiratory failure requiring mechanical ventilation for more than 48 hours and coagulopathy are two strong, independent risk factors for bleeding. Splanchnic hypoperfusion is the underlying etiology of stress-related mucosal injury and bleeding. Mucosal damage typically manifests as multiple superficial lesions without perforation, and bleeding often originates in superficial capillaries after the patient is admitted to the intensive care unit. Providing adequate visceral perfusion is vital to preventing bleeding. Gastrointestinal function should be taken into consideration before using enteral nutrition, and enteral nutrition should not be the sole stress ulcer prophylactic therapy. Acid-suppression therapy should be used to raise the intragastric pH above 3.5 because it reduces the incidence of stress-related mucosal bleeding. Proton pump inhibitors are at least as effective, and may be more effective than histamine H 2-receptor antagonists in achieving this pH goal and preventing bleeding. Conclusion. The key to reducing mortality from stress-related bleeding in critically ill patients is to prevent mucosal damage. Providing adequate visceral perfusion and acid-suppression therapy can reduce the risk of stress-related mucosal damage and bleeding.

KW - Critical illness

KW - Gastrointestinal drugs

KW - Gastrointestinal hemorrhage

KW - Mortality

KW - Nutrition

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=18644377612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644377612&partnerID=8YFLogxK

M3 - Article

C2 - 15905595

AN - SCOPUS:18644377612

VL - 62

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - SUPPL. 2

ER -